Legend Biotech Corporation (LEGN) AI Stock Analysis

Legend Biotech Corporation is a clinical-stage biopharmaceutical firm and subsidiary of Genscript Biotech Corporation dedicated to pioneering novel cell therapies for oncology and other critical medical indications across the globe, including the United States and China. Its lead asset, LCAR-B38M, is a chimeric antigen receptor therapy under evaluation for multiple myeloma. The company also maintains a pipeline of early-stage autologous cell therapy candidates in Phase I trials for gastric cancer and T cell lymphoma. In addition, Legend Biotech is advancing CAR-T therapies targeting CD20, CD22, and CD19 for various lymphomas and leukemias, and collaborates with industry partners including Janssen Biotech, Inc.

Revenue expanded from $68.8M in FY2021 to $1.03B in FY2025, driven by revenue growth of 70.0% in FY2022, 143.7% in FY2023, 120.0% in FY2024, and 64.0% in FY2025. Gross margin was 60.3% in FY2025, while operating margin improved from -570.0% in FY2021 to -13.3% in FY2025. Annual net income was -$296.8M in FY2025, compared to -$403.6M in FY2021 and -$177.0M in FY2024. For the trailing twelve months ended June 30, 2026, revenue totaled $1.27B, backed by quarterly revenue growth of 51.9% year-over-year and an operating margin of 14.9%, although profit margin remained negative at -7.2%.

As of June 30, 2026, Legend Biotech held $964.6M in cash and short-term investments alongside total debt of $278.2M, resulting in net cash of $686.4M. Total assets stood at $1.75B against shareholders' equity of $1.23B, supported by a current ratio of 3.04 and a debt-to-equity ratio of 0.23. Operating cash flow in FY2025 was -$100.5M, free cash flow was -$168.0M, and capital expenditures were $67.6M. Over 5 years, the company's share count increased 32.2%.

Legend Biotech trades at a forward P/E of 27.5x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales ratio of 2.8x sits below the peer median of 4.1x, while its EV-to-EBITDA ratio of 252.3x stands above the peer median of 12.0x. As of October 16, 2026, the stock posted a 1-year return of -42.9%, trailing the S&P 500 return of 16.8%. Over 5 years, the stock logged a return of -64.4% versus 83.0% for the S&P 500.

Wall Street analysts hold 3 Strong Buy, 5 Buy, and 5 Hold ratings on Legend Biotech, with 0 Sell or Strong Sell ratings. The mean price target of $45.62 indicates potential upside of 146.9% from the last close of $18.48. For the fiscal year ending December 31, 2026, the consensus revenue estimate is $1.44B alongside an EPS estimate of -$0.01. For the following fiscal year, 2 analysts project revenue of $1.77B and EPS of $0.68. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Legend Biotech Corporation (LEGN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LEGN income statement, LEGN balance sheet, LEGN key metrics, LEGN analyst forecast, LEGN chart. See the LEGN stock overview for the latest quote and news.